Furthermore, IL23 overexpression boosted IL17 signaling and attenuated the anti-HCC effects of miR-22, indicating that miR-22 treatment was partly mediated by the inhibition of inflammatory IL17A signaling. Here, IL17A is linked to hepatocellular carcinoma.